AUTHOR INDEX

Back, D. J. 147
Bell, C. 157
Breimer, D. D. 407, 445

Calabrese, E. J. 285, 297
Canada, A. T. 285, 297
Coughlin, S. 107

de Boer, A. G. 407
de Graan, P. N. E. 63
Docherty, J. R. 241
Drlica, K. 107

Eberle, A. N. 63

Gardiner, P. J. 1
Glue, P. 309

Humphries, M. J. 85

Itoh, M. 351

Kehrer, J. P. 123
Klevit, R. E. 181

Laerum, O. D. 335

Nutt, D. J. 309

Olden, K. 85
Orme, M. L'E. 147

Paukovits, W. R. 335

Schellens, J. H. M. 445
Scimonelli, T. 63
Sedwick, W. D. 181
Solca, F. 63
Soons, P. A. 445
Starnes, J. W. 123

van Hoogdalem, E. J. 407
Veigl, M. L. 181

AUTHOR INDEX

Back, D. J. 147
Bell, C. 157
Breimer, D. D. 407, 445

Calabrese, E. J. 285, 297
Canada, A. T. 285, 297
Coughlin, S. 107

de Boer, A. G. 407
de Graan, P. N. E. 63
Docherty, J. R. 241
Drlica, K. 107

Eberle, A. N. 63

Gardiner, P. J. 1
Glue, P. 309

Humphries, M. J. 85

Itoh, M. 351

Kehrer, J. P. 123
Klevit, R. E. 181

Laerum, O. D. 335

Nutt, D. J. 309

Olden, K. 85
Orme, M. L'E. 147

Paukovits, W. R. 335

Schellens, J. H. M. 445
Scimonelli, T. 63
Sedwick, W. D. 181
Solca, F. 63
Soons, P. A. 445
Starnes, J. W. 123

van Hoogdalem, E. J. 407
Veigl, M. L. 181

SUBJECT INDEX

Absorption enhancement, intestinal
  drugs 407–33
Adenylate cyclase, α_2-adrenoceptors 266–68
Ageing
  α-adrenoceptor responsiveness 268
  catalase 303, 304
  superoxide dismutase activity 290–92
Airway smooth muscle
  eicosanoid action 46–51
    AMP 49, 50
    calcium 47–49
    inositol phospholipid 50
  and eicosanoids 1–52
    biosynthesis 2–4
    biosynthetic scheme 3
  hyperactivity and eicosanoids 32–35
  isolated and eicosanoids 7–36
    cat 18, 19
    dog 19–21
    guinea pig 8–12
    human 22–31
    monkey 21, 22
    rat 16, 17
  metabolism 4–7
  uptake 4
Antidepressants
  anxiety 318–22
  clinical pharmacology 309–27
  mechanism and noradrenergic function 324, 325
Anxiety
  benzodiazepines 317
  and depresssion relationship 312–14
  diagnostic classification 309–11
  tricyclic antidepressants 322, 323
Anxiolytics, clinical pharmacology 309–27
Asparagine-linked oligosaccharides, tumor metastases 85–99
Asthmatics, leukotrienes and airways in man 30, 31
Autoantibodies, serum in diabetes 355–61
Autoimmunity 352, 353
Azone, gastrointestinal absorption enhancement 429, 430

Benzodiazepines, anxiety 317, 318
Bile salts, gastrointestinal absorption enhancement 418–20

Calcium
  α-adrenoceptors 265, 266
  hypoxia and ischaemia markers 137, 138
Calcium binding agents, gastrointestinal absorption enhancement 427, 428
Calmodulin
  activities and antagonists 212–14
  antagonist specificity 210, 211
  circular dichroism 207
  drug binding sites 201
  drug target 187
  nuclear magnetic resonance 207–10
  -regulated enzymes 183–87
  spectroscopic studies 204–207
  structure 181, 182
  structure–function probes 203–11
Calmodulin antagonists 181–229
  anticancer agents 218, 219
  binding properties 196–99
  calmodulin activity 212–14
  DNA interactive drug modification 219–25
    bleomycin 221, 223, 224
    DNA repair 222–24
  hydrophobic 200–202
  inhibitory properties 196–99
  neuroleptic drugs 217, 218
  peptides 203
  pharmacodynamics 214–17
  pleiotropic drug resistance 225–28
  structure 188–95
  therapeutic uses 214–19
  types 187
Cardiac reperfusion injury
  age 132–34
  cell culture 126, 127
  definition 123, 124
  hypoxia 130, 131
  in vitro 126–30
  markers 125
    experimental 135–38
  mechanisms 138
  models 124, 126
  pathways 139, 140
  perfused preparation 128–30
  Purkinje fiber 127, 128
Carnitine derivatives and gastrointestinal absorption 430
Castanospermine structure 96
Catalase
  age effects 303, 304
  disease 299
  genetics 298
  inducers 299, 300
  inhibition 300, 301
  peroxisome 301
  species variability 302, 303
  toxicology 298
  xenobiotic detoxification 297–304
Clomipramine, panic patients 320
Coumarins
  DNA replication 108
  DNA supercooling 108
  eukaryotic effects 109, 110
Cyclosporin, diabetes prevention 377–79
Cytoskeleton and calmodulin 183

Depression
  anxiety coexistence 313, 314
  diagnostic classification 311–13
  pharmacology 316

Diabetes, α-adrenoceptor responsiveness 269
Diabetes mellitus
  autoantibodies 355–61
    anti-insulin 358
    islet cell cytoplasmic 355–57
    islet cell surface 357, 358
  HLA-D region 353–55
  immune complexes 361, 362
  immunological aspects 351–82
DNA damage
  alkylating agent toxicity 224, 225
  calmodulin inhibitors 221–25
DNA gyrase inhibitors 107–16
  bacterial cell sensitivity factors 114
  cell death 114
  lesion repair 113
  mutations and survival 115, 116
Dopaminergic neurons, peripheral 157–75
  biochemical features 158–60
  distribution 166–75
    gastrointestinal 172, 173
    kidney 166–71
    lung 173, 174
    reproductive 173
  histochemical features 160–63
  identification 157–66
  pathway 158
  pharmacological features 164–66
  ultrastructural features 163, 164
Drug interactions, tolbutamine
    metabolism 150–53

Eicosanoids, airway smooth muscle 1–52
Enamines, gastrointestinal absorption 424, 425

Fatty acids, gastrointestinal absorption 421, 422

Gastrointestinal drug absorption 407–409
  barriers 409–11
  enhancers 411–32
  structure 407–409
Glycerides, gastrointestinal absorption 422–24
Glycoprotein processing, metastatic cells 86–88

Hemoregulators, peptide 335–46
  chemical properties 336
  clinical applications 345, 346
  history 335, 336
  monomer-dimer regulatory system 342–44
  properties 339–42
  purification 337

Imipramine, panic attacks 319
Immune complexes in diabetes 361, 362
Inhibitors
  DNA gyrase 107–16
  metastatic 94–99
Insulin-dependent diabetes mellitus (IDDM)
  animal models 369–77
    NOD mouse 375, 376
    NZB mouse 376, 377
    spontaneous 372–75
    streptozotocin 369–71
  free radical scavengers 380–82
  immunosuppression 379, 380
  lymphocyte reconstitution 379
  prevention 377–82
Insulitis
  antiimmune responses 363
  killer cells 367, 368
  lymphocyte function 368
  macrophages 366
  T lymphocytes 364–66

Kidney, dopaminergic neurons 166–72
  function 167–70
  pathophysiology 171, 172

Lectin-resistant mutants, metastatic
    potential 91–94
Leukotrienes
  airways smooth muscle hyperactivity 35, 36
  guinea pig airways smooth muscle 12–15
  human isolated smooth muscle 27–30
  metabolism 6, 7
  rat isolated smooth muscle 17
  therapeutic uses 52
Liposomes, gastrointestinal absorption 428, 429

Malignancy markers 90
Melanocyte stimulating hormone (MSH)
  features 63, 65
  photoaffinity labels 65
    biological activity 67
    derivatives 66
  structures 64
Melanophores, u.v. irradiation 68, 69
  apparatus 69
Metastases *see also* tumor metastases
  functional defects 93, 94
  glycoprotein processing inhibitors 94–99
  lectin-resistant mutants 91–94
Mixed micelles, gastrointestinal
    absorption 425–427
Models
  cardiac reperfusion injury 124, 126
  diabetes 369–77
Monoamine oxidase inhibitors, panic
    attacks 320, 321
Multipotent stem cells 340
Myelopoietic progenitor cells 339, 340

Nifedipine
  area under curve 448, 449
  biotransformation 446
  excretion 447
  pharmacokinetics 449
  population studies 445–50
  variability in disposition kinetics 450–52
Non-steroidal anti-inflammatory drugs,
    gastrointestinal absorption 413–16
Nuclear magnetic resonance, calmodulin 207–10

Panic attacks 316, 319, 320
  combination pharmacotherapy 321
  psychological treatment 325, 326
Phenothiazines, gastrointestinal absorption 428
Photoaffinity labeling, MSH receptors 63–80
  melanoma cells 76–79
  melanophores 67–76

Polyacrylic acid, gastrointestinal absorption enhancement 431, 432
Prostanoids *see also* eicosanoids
  airways smooth muscle 1, 2
  therapeutic uses 51, 52
Protein kinases and calmodulin 184

Quinolones
  bacterial DNA 110, 111
  DNA supercooling 111
  DNA synthesis inhibition 112

Receptors, alpha$_1$ adrenergic
  agonist, therapeutic uses 270, 271
  antagonist uses 271–73
  functional subdivision 247–51
    criteria 251–55
    implications 265–68
  molecular biology 269, 270
  pharmacology 241–73
  prejunctional 242, 244
  pre- and postjunctional 244, 245
  rat anococcygens 246, 247
  subdivision 245
Receptors, alpha$_2$ adrenergic
  agonist, uses 270, 271
  antagonist uses 271–73
  inhibitory, evidence 243
  molecular biology 269, 270
  pharmacology 241–73
  prejunctional 241, 242
  pre- and postjunctional 244, 245
  subdivision 255
    binding studies 257, 258
    functional 258–62
    implications 265–8
    prejunctional 255, 256
Receptor, antiinsulin antibodies 360
Receptors, eicosanoid 36–46
  classification 37
Receptors, leukotrienes
  antagonist structure 42, 43
  classification, airways 44
  functional studies 40
  human bronchial muscle 44
Receptors, MSH 63–80
  malanoma cells 76–79
    characterization 78, 79
    stimulation 77
    u.v. irradiation 77
  melanophores 67, 68
    Anolis 73–76
    forskolin action 75, 76
    Xenopus 69–72
  photoaffinity labeling 67–80
Receptors, prostanoid
  antagonists 38
  classification, airways 37–39

Saponins, gastrointestinal absorption 431
Sodium tauro-24,25-dihydrofusidate, gastrointestinal absorption 420, 421
Stress
  anxiety 315
  panic attacks 316
Superoxide
  sources 285, 286
  xenobiotic toxicity 286, 287
Superoxide dismutase
  age effects 290–92
  distribution 287, 288
  genetic aspects 287
  inducers 288–90
  modulation 288
  xenobiotic detoxification 285–91
Surfactant, gastrointestinal absorption 416–18
Swainsonine structure 96

Tolbutamine
  cytochrome P-450 and hydroxylation 150–52
  drug interactions 150–53
  metabolism 147–49
    genetic control 149, 150
    pathways 148
  pharmacokinetics 148
Tumor metastases
  asparagine-linked oligosaccharides 85–99
  carbohydrate structure 86–91
  lectin binding cells 89, 90
  process 85
Tunicamycin
  metastasis 95, 96
  structure 96

Variable receptor affinity hypothesis 262, 263

Xenobiotic detoxification
  catalase 297–304
  superoxide dismutase 285–92


1.0
1.1
1.25
1.4
1.6
2.8
3.2
3.6
4.0
2.5
2.2
2.0
1.8